The latest price target for RXO (NYSE:RXO) was reported by Goldman Sachs on February 6, 2025. The analyst firm set a price target for $24.00 expecting RXO to rise to within 12 months (a possible 19.17% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for RXO (NYSE:RXO) was provided by Goldman Sachs, and RXO maintained their neutral rating.

There is no last upgrade for RXO

The last downgrade for RXO Inc happened on November 12, 2024 when Citigroup changed their price target from $33 to $33 for RXO Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RXO, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RXO was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.

While ratings are subjective and will change, the latest RXO (RXO) rating was a maintained with a price target of $28.00 to $24.00. The current price RXO (RXO) is trading at is $20.14, which is out of the analyst’s predicted range.